The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Yajing Zhu(Karolinska University Hospital), Theodoros Foukakis(Karolinska Institutet), Ellinor Elinder(Stockholm South General Hospital), Thomas Hatschek(Karolinska University Hospital), Alexios Matikas(Karolinska University Hospital), Erika Isaksson-Friman(Saint Göran Hospital), Ana Bosch(Memorial Sloan Kettering Cancer Center), Lena Carlsson(University of Gothenburg), Mattias Bergqvist(Biovica (Sweden)), Ivette Raices Cruz(Karolinska Institutet), Zakaria Einbeigi, Mats Hellström(Karolinska University Hospital), Henrik Lindman(Uppsala University), Jonas Bergh(Karolinska Institutet), Hemming Johansson(Karolinska Institutet), Anne Andersson(Umeå University), Ioannis Zerdes(Karolinska University Hospital), Kang Wang(Hebei North University), Ann Charlotte Dreifaldt(Örebro University Hospital)
Cited by 6
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k